Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 6021-6030 Newer>

The Motley Fool November 18, 2009 Brian Orelli	VIVUS Gets a Spark A new erectile-dysfunction drug shows promise.
The Motley Fool November 17, 2009 Brian Orelli	Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount
The Motley Fool November 17, 2009 Brian Orelli	This Partnership Is Smoking! Glaxo and Nabi team up for smokers who want to quit. Let's just hope they don't flame out in phase 3 trials.
The Motley Fool November 17, 2009 Dave Mock	A Big Upgrade for Sanofi-Aventis This bullish call comes from more than just one analyst.
The Motley Fool November 16, 2009 Brian Orelli	Music to Health-Care Investors' Ears Are faster FDA review times coming?
The Motley Fool November 16, 2009 Amanda B. Kish	The Hottest Sector for 2010 It's hard to argue that the potential benefits to this sector won't be significant if health care reform does work its way through. The time to stock up on high-quality health-care names is now.
The Motley Fool November 16, 2009 Brian Orelli	Abbott Puts a Nail in Merck's Coffin There's a clear winner from the American Heart Association conference.
CRM November 2009 Lauren McKay	Pharmaceuticals -- CRM Undergoes an Experimental New Treatment An older CRM vertical gets a new dose of on-demand technology.
The Motley Fool November 13, 2009 Brian Orelli	Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials.
The Motley Fool November 13, 2009 Brian Orelli	Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant.
<Older 6021-6030 Newer> Return to current articles.